XM does not provide services to residents of the United States of America.
B
B

Biomarin

News

U.S. STOCKS IDEXX, Amgen, Airbnb

BUZZ-U.S. STOCKS ON THE MOVE-IDEXX, Amgen, Airbnb Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
I
U
U
F
M
R
U
V
M

U.S. STOCKS Lumen Technologies, Broadridge Financial, IDEXX

BUZZ-U.S. STOCKS ON THE MOVE-Lumen Technologies, Broadridge Financial, IDEXX Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
C
I
U
U
F
M
R
T
U
B
J
M

BioMarin up as investors applaud new focus for hemophilia gene therapy

BUZZ-BioMarin up as investors applaud new focus for hemophilia gene therapy ** Shares of BioMarin Pharmaceutical BMRN.O rise ~8% to hit over 3-month high of $86.48 ** BMRN plans to cut direct annual expenses for its hemophilia gene therapy, Roctavian , by directing commercial focus to markets in the U.S., Germany and Italy ** Co anticipates reducing annual direct expenses on Roctavian to ~$60 million beginning in 2025 ** "Investors appear to be applauding the decision to downsize Roctavian's exp
B

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T

U.S. Actinium, Albemarle, ArcBest

U.S. RESEARCH ROUNDUP- Actinium, Albemarle, ArcBest Aug 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Actinium Pharmaceuticals, Albemarle and ArcBest, on Tuesday. HIGHLIGHTS * Actinium Pharmaceuticals Inc ATNM.A : JonesTrading cuts PT to $9 from $26 * Albemarle ALB.N : Baird cuts to neutral; cuts target price to $85 from $102 * ArcBest Corp ARCB.O : Stephens cuts target price to $130 from $145 * Crispr Therapeuti
A
A
B
B
C
C
C
C
D

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.